Group 1: Investor Relations Activities - The investor relations activities included specific object research and analyst meetings, with a total of 15 participants from various institutions [2] - The meetings took place on February 19 and 20, 2024, at the company's conference room [2] Group 2: Product Performance and Market Strategy - The implementation of centralized procurement for the product "Tenghuang Jianbone Tablets" has been executed across all supply provinces, with most provinces starting in October-November 2023 [2] - "Xuanqi Jianbone Tablets" are suitable for treating mild to moderate knee osteoarthritis, while "Tenghuang Jianbone Tablets" are used for various degenerative joint diseases [3] - The company aims to achieve sales of 200-300 million RMB for "Noni Granules" within 3-5 years post-launch, although market conditions may affect actual sales [3] Group 3: Research and Development Progress - The company is conducting long-term toxicity tests for "Noni Granules" in compliance with GLP standards, with plans to resume research registration after testing [3] - Other R&D projects include "Zhilong Tongluo Tablets," "Jianwei Qutong Pills," and "Yiqi Xiaoliu Granules," with "Jianwei Qutong Pills" currently in phase III clinical trials expected to apply for production in 2025 [4] Group 4: Operational Strategy and Market Outlook - The company will focus on channel expansion and quality improvement, aiming to enhance market share for centralized procurement products [5] - The management is optimistic about the overall business situation for 2024, with plans to submit budget indicators for board review [5] - There is a risk warning regarding the uncertainty of achieving operational goals due to market conditions and operational environments [5]
方盛制药(603998) - 投资者关系活动记录表